Toggle navigation
About
About The ASCO Post
Editorial Board
Rights and Permissions
Contact
Subscribe
News
FDA Update
Journal Spotlight
Expert's Corner
In the Clinic
View By Issue
View All
Meetings
IASLC WCLC 2025
SOHO 2025
22nd ASBrS Annual Meeting
EHA 2025 Congress
2025 ASCO Annual Meeting
Calendar
View All
Topics
Breast Cancer
Lung Cancer
Prostate Cancer
Lymphoma
Cardio-oncology
View All
Videos
Newsreels
Video Roundtables
Podcasts
Subscribe
Advertisement
Topics
Advertisement
Solid Tumors
Bladder Cancer
Breast Cancer
CNS Cancers
Colorectal Cancer
Gastroesophageal Cancer
Gastrointestinal Cancer
Gynecologic Cancers
Head and Neck Cancer
Hepatobiliary Cancer
Kidney Cancer
Lung Cancer
Pancreatic Cancer
Prostate Cancer
Sarcoma
Skin Cancer
Thyroid Cancer
Neuroendocrine Tumors
Hematologic Malignancies
Leukemia
Lymphoma
Multiple Myeloma
Myelodysplastic Syndromes
Issues in Oncology
Cardio-oncology
Cost of Care
COVID-19
Genomics/Genetics
Geriatric Oncology
Global Cancer Care
Health-Care Policy
Immunotherapy
Legislation
Survivorship
Supportive Care
Integrative Oncology
Pain Management
Palliative Care
Symptom Management
Advertisement
Advertisement
Sep
15
Today In Oncology
Novel ADC Under Study in Previously Treated EGFR-Mutated NSCLC
New Subcutaneous Amivantamab Combo Dosing Schedule Shows Safety and Efficacy in EGFR-Positive NSCLC
STAS Predicts Prognosis in Early NSCLC Regardless of Surgical Approach
Hypofractionated vs Conventional Radiotherapy in Phase III Trial for LS-SCLC
Tarlatamab and Anti-PD-1 Therapy as First-Line Maintenance for ES-SCLC
View More
Advertisement
